-

Global Transmucosal Drug Delivery Devices Pipeline Landscape Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Transmucosal Drug Delivery Devices Pipeline Landscape Report 2021" has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information about the Transmucosal Drug Delivery Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Scope

  • Extensive coverage of the Transmucosal Drug Delivery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transmucosal Drug Delivery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Transmucosal Drug Delivery Overview

3 Products under Development

3.1 Transmucosal Drug Delivery - Pipeline Products by Stage of Development

3.2 Transmucosal Drug Delivery - Pipeline Products by Segment

3.3 Transmucosal Drug Delivery - Pipeline Products by Territory

3.4 Transmucosal Drug Delivery - Pipeline Products by Regulatory Path

3.5 Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date

3.6 Transmucosal Drug Delivery - Ongoing Clinical Trials

4 Transmucosal Drug Delivery - Pipeline Products under Development by Companies

4.1 Transmucosal Drug Delivery Companies - Pipeline Products by Stage of Development

4.2 Transmucosal Drug Delivery - Pipeline Products by Stage of Development

5 Transmucosal Drug Delivery Companies and Product Overview

5.1 AcelRx Pharmaceuticals Inc Company Overview

5.2 AFYX Therapeutics A/S Company Overview

5.3 Albert Einstein College of Medicine Company Overview

5.4 Allergan Ltd Company Overview

5.5 Altamira Medica AG Company Overview

5.6 Amphastar Pharmaceuticals Inc Company Overview

5.7 Anelleo Inc Company Overview

5.8 APR Applied Pharma Research SA Company Overview

5.9 ARS Pharmaceuticals Inc Company Overview

5.10 Auris Medical AG Company Overview

5.11 Auritec Pharmaceuticals Inc Company Overview

5.12 Bayer Healthcare LLC Company Overview

5.13 BeFree! Company Overview

5.14 Bespak Europe Ltd Company Overview

5.15 Biorings LLC Company Overview

5.16 BioXcel Therapeutics Inc Company Overview

5.17 Bryn Pharma LLC Company Overview

5.18 Callitas Therapeutics Inc Company Overview

5.19 Combinent BioMedical Systems Inc Company Overview

5.20 Conrad Company Overview

5.21 Dare Bioscience Inc Company Overview

5.22 Eledon Pharmaceuticals Inc Company Overview

5.23 Emergent BioSolutions Inc Company Overview

5.24 Ena Respiratory Pty Ltd Company Overview

5.25 Eureka Therapeutics Inc Company Overview

5.26 Evestra Inc Company Overview

5.27 EyeGate Pharmaceuticals Inc Company Overview

5.28 Ferring Pharmaceuticals AS Company Overview

5.29 Ghent University Company Overview

5.30 Glenmark Pharmaceuticals Ltd Company Overview

5.31 Grunenthal Ltd Company Overview

5.32 Hebrew University of Jerusalem Company Overview

5.33 Hikma Pharmaceuticals Plc Company Overview

5.34 Insys Therapeutics Inc (Inactive) Company Overview

5.35 IntelGenx Corp Company Overview

5.36 ITF Pharma Inc Company Overview

5.37 Janssen Sciences Ireland UC Company Overview

5.38 Karessa Pharma AB Company Overview

5.39 Kytogenics Pharmaceuticals Inc Company Overview

5.40 Laboratoire HRA Pharma SAS Company Overview

5.41 Laboratorios Andromaco Company Overview

5.42 Lyra Therapeutics Inc Company Overview

5.43 McNeil AB Company Overview

5.44 Medlab Clinical Ltd Company Overview

5.45 Merck & Co Inc Company Overview

5.46 Merck Serono SA Company Overview

5.47 Merck Sharp & Dohme Ltd Company Overview

5.48 Mithra Pharmaceuticals SA Company Overview

5.49 Mucommune LLC Company Overview

5.50 Mystic Pharmaceuticals Inc Company Overview

5.51 Nanosys Inc Company Overview

5.52 Nasus Pharma Ltd Company Overview

5.53 Nemera La Verpilliere Company Overview

5.54 NorInvent AB Company Overview

5.55 Opiant Pharmaceuticals Inc Company Overview

5.56 OptiNose AS Company Overview

5.57 OptiNose Inc Company Overview

5.58 Orion Biotechnology Canada Ltd Company Overview

5.59 Orphanse Healthcare SAS Company Overview

5.60 Oyster Point Pharma Inc Company Overview

5.61 Palette Life Sciences AB Company Overview

5.62 Phoenix Life Sciences International Ltd Company Overview

5.63 RDD Pharma Ltd (Inactive) Company Overview

5.64 Renown Pharmaceuticals Pvt Ltd Company Overview

5.65 Rhinomed Limited Company Overview

5.66 Scientus Pharma Inc Company Overview

5.67 Seelos Therapeutics, Inc. Company Overview

5.68 Shin Nippon Biomedical Laboratories Ltd Company Overview

5.69 SipNose Ltd Company Overview

5.70 Starpharma Holdings Ltd Company Overview

5.71 Suda Pharmaceuticals Ltd Company Overview

5.72 Therakind Ltd Company Overview

5.73 University of Pittsburgh Company Overview

5.74 University of South Florida Company Overview

5.75 University of Texas at Austin Company Overview

5.76 University of the Witwatersrand Company Overview

5.77 University of Washington Company Overview

5.78 VistaGen Therapeutics Inc Company Overview

5.79 Washington University in St Louis Company Overview

5.80 Xlear Inc Company Overview

5.81 Zosano Pharma Corp Company Overview

5.82 Zydus Healthcare Ltd Company Overview

6 Transmucosal Drug Delivery- Recent Developments

For more information about this report visit https://www.researchandmarkets.com/r/ib1dg3

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Virtual PBX Market Forecast 2025-2032: Integration of Secure End-to-End Encryption and Multi-Factor Authentication Enhancing Virtual PBX Security Compliance Standards - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Virtual PBX Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The virtual PBX market is rapidly evolving as organizations accelerate the adoption of cloud-based communication to meet new operational demands. This trend, driven by shifting work models and the need for flexible, scalable technology, is transforming business communications globally. Market Snapshot: Virtual PBX Market Growth and Opportunities The Virtual P...

Government Cloud Market Analysis and Forecast 2025-2032: Top Strategies for Public Sector Leaders Adopting Government Cloud Solutions - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Government Cloud Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. Government agencies worldwide are rapidly transforming digital strategies with the adoption of government cloud solutions, driven by a heightened focus on security, compliance, and inter-agency collaboration. The public sector's shift toward cloud computing is fundamentally altering operational models, presenting both challenges and opportunities for sen...

Death Care Services Markets | Global Forecast 2025-2032 | Technological Integration and Personalized Services Driving Market Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Death Care Services Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The Death Care Services market is experiencing robust growth, transitioning from USD 106.05 billion in 2024 to USD 113.01 billion in 2025, with expectations to reach USD 179.50 billion by 2032 at a CAGR of 6.79%. This transformation is driven by demographic shifts, consumer preferences, and regulatory changes, compelling service providers to innovate and ada...
Back to Newsroom